This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Jul 2017

Pall introduces proprietary bioreactor control system

The mPath bioreactor control system is the first to be developed and delivered by a technology supplier specifically for their product line, allowing full access to bioreactor capabilities that current commercial solutions cannot provide.

Pall Corporation has introduced the mPath bioreactor control system to the biopharmaceutical market. The mPath benchtop bioreactor control system is a first-of-its-kind solution to deliver accurate measurement and control of single-use process development-scale bioprocesses. It will support the Allegro XRS 25 bioreactor, with further expansions planned for the mPath portfolio in 2017 and beyond.

“Throughout the development of the mPath bioreactor control system, our team was focused on simplifying single-use lab-scale bioprocesses with a functional, integrated user experience,” explained Loe Cameron, Director of Analytics and Controls at Pall. “The architecture makes plug-and-play connectivity a reality, while providing access to features of Pall bioreactors that other commercial control options do not allow. In addition, the mPath bioreactor control system has been designed to support characterization and optimization, and is compliant with cGMP regulations.”

An expandable control and data management system includes both bioreactor control towers and an advanced supervisory control and data acquisition (SCADA) software package. The mPath control tower is cleanroom-ready after being IP54 designed and tested, and comes with features such as six mass flow controllers (MFCs) as standard. There are three variable speed pumps for feeds, titrants and media fills, and three biocontainer hangers with integrated load cells to organize and weigh titrants, feeds and media with a minimal footprint. All of this comes at no additional cost to buyers, and there are no limits on the number of systems or users that can run the control software.

“At Pall, we remain driven to advance the biopharmaceutical industry by delivering innovative total solutions to end users,” said Martin Smith, Chief Technology Officer at Pall. “The launch of the mPath bioreactor control system represents the first in our next generation of unifying technologies for a seamless, fully controlled, and value-based user experience.”

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.